Please review this important safety information carefully before starting any treatment plan. This page is not a substitute for medical advice from your licensed healthcare provider.

About Curve Health

Curve Health is a telehealth platform that connects patients with licensed, independent healthcare providers. Curve Health does not provide medical advice, diagnose conditions, prescribe medication, or fulfill prescriptions. Curve Health is not a pharmacy and is not licensed as a medical provider. All treatment decisions are made solely by licensed providers based on individual clinical evaluation.

Semaglutide — Safety Information

Semaglutide is a GLP-1 receptor agonist. The following safety information applies to both FDA-approved semaglutide products and compounded semaglutide formulations.

‍

Contraindications

Do not use semaglutide if you have:

• A personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• A known hypersensitivity to semaglutide or any product components

‍

Warnings and Precautions

Tell your healthcare provider before starting treatment if you have or have had:

• Pancreatitis or a history of pancreatitis
• Kidney problems or kidney disease
• Diabetic retinopathy (if you have type 2 diabetes)
• Gallbladder problems
• Depression, suicidal thoughts, or mental health conditions
• Allergic reactions to any GLP-1 receptor agonist

‍

Common Side Effects

The most common side effects include:

• Nausea
• Diarrhea
• Vomiting
• Constipation
• Abdominal pain
• Headache
• Fatigue
• Decreased appetite
• Dizziness
• Injection site reactions

Most side effects are mild to moderate and tend to improve over time as your body adjusts to the medication. Side effects are often most pronounced during dose escalation.

‍

Serious Side Effects

Seek immediate medical attention if you experience:

• Signs of thyroid tumors: A lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath
• Pancreatitis: Severe, persistent abdominal pain that may radiate to the back, with or without vomiting
• Allergic reactions: Swelling of the face, lips, tongue, or throat; difficulty breathing; rapid heartbeat; rash or itching
• Hypoglycemia: Dizziness, blurred vision, anxiety, irritability, sweating, slurred speech, or confusion — especially if taking insulin or sulfonylureas
• Kidney injury: Changes in urination, swelling in legs or ankles
• Gallbladder problems: Upper stomach pain, fever, clay-colored stools, yellowing of skin or eyes (jaundice)

‍

Drug Interactions

Semaglutide may interact with other medications. Tell your provider about all medications you are taking, including:

• Insulin or sulfonylureas: Risk of hypoglycemia may increase; dose adjustments may be needed
• Oral medications: Semaglutide slows gastric emptying, which may affect the absorption of oral medications. Discuss timing of doses with your provider
• Warfarin or other anticoagulants: Monitor INR more frequently when starting or changing semaglutide dosing

‍

The above safety information is provided for educational purposes and does not cover all possible uses, warnings, precautions, drug interactions, or adverse effects. This information has not been evaluated by the Food and Drug Administration. Compounded tirzepatide is not FDA-approved. Consult your licensed healthcare provider for complete information.

Pregnancy and Breastfeeding

Do not use GLP-1 receptor agonist medications if you are pregnant, plan to become pregnant, or are breastfeeding.

‍

• Animal studies have shown that GLP-1 receptor agonists may cause harm to a developing fetus. There is insufficient data in humans to determine the risk during pregnancy.
• Discontinue treatment at least 2 months before a planned pregnancy due to the long half-life of these medications. Notify your provider immediately if you become pregnant during treatment.
• It is not known whether semaglutide or tirzepatide passes into breast milk. Due to the potential for adverse effects in a nursing infant, breastfeeding is not recommended during treatment.
• If you are of childbearing potential, discuss appropriate contraceptive methods with your provider before starting treatment.

Storage and Handling

• BEFORE FIRST USE: Store in a refrigerator at 36°F to 46°F (2°C to 8°C). Do not freeze. Do not use if the product has been frozen.

‍

‍

• AFTER FIRST USE: May be stored at room temperature below 86°F (30°C) or refrigerated. Use within the timeframe specified on your product label (typically 21–28 days, depending on formulation).

• Protect from light and excessive heat.
• Do not use if the solution is discolored, cloudy, or contains particles.
• Keep out of the reach of children.
• Dispose of needles and syringes in an FDA-cleared sharps container. Do not dispose of loose needles in household trash.

When to Contact Your Provider

Contact your Curve Health provider if you experience:

‍

• Side effects that are severe, persistent, or worsening
• New or unusual symptoms after starting or changing a dose
• Difficulty administering your medication
• Questions about drug interactions with new medications
• Changes in your health status or medical history

‍

For medical emergencies, call 911 immediately. Do not wait to contact your Curve Health provider in an emergency.

Reporting Adverse Events

If you experience a serious adverse event or side effect, you are encouraged to report it to:

‍

FDA MedWatch — The FDA Safety Information and Adverse Event Reporting Program

Online: www.fda.gov/medwatch

Phone: 1-800-FDA-1088 (1-800-332-1088)

‍

You should also report any adverse events to your Curve Health provider and to the dispensing pharmacy.

Consult Your Provider

This page is provided for informational purposes only and does not constitute medical advice. It does not cover all possible uses, warnings, precautions, drug interactions, or adverse effects. Always consult with your licensed healthcare provider before starting, stopping, or changing any treatment. Your provider will review your complete medical history and current medications to determine if a treatment plan is appropriate for you.

‍

Last updated: June 5, 2026